PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
1.580
-0.020 (-1.25%)
Apr 28, 2026, 4:00 PM EDT - Market closed
PepGen Employees
PepGen had 56 employees as of December 31, 2025. The number of employees decreased by 25 or -30.86% compared to the previous year.
Employees
56
Change (1Y)
-25
Growth (1Y)
-30.86%
Revenue / Employee
n/a
Profits / Employee
-$1,600,982
Market Cap
109.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56 | -25 | -30.86% |
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Dec 31, 2023 | 64 | 19 | 42.22% |
| Dec 31, 2022 | 45 | 14 | 45.16% |
| Dec 31, 2021 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Cibus | 118 |
| Verrica Pharmaceuticals | 76 |
| Pyxis Oncology | 56 |
| Biomea Fusion | 41 |
| Oncolytics Biotech | 29 |
| Genelux | 26 |
| Cognition Therapeutics | 14 |
PEPG News
- 4 weeks ago - PepGen Transcript: Study update - Transcripts
- 4 weeks ago - PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 4 weeks ago - PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data - Business Wire
- 7 weeks ago - PepGen Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - US FDA puts partial clinical hold on PepGen's muscle disease drug trial - Reuters
- 7 weeks ago - PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights - Business Wire
- 7 weeks ago - PepGen Announces Regulatory Updates on FREEDOM2 - Business Wire
- 2 months ago - PepGen to Participate in the Leerink Global Healthcare Conference - Business Wire